retatrutide phase 3 triumph produces up to 30.3% weight loss in trial Eli Lilly's New Weight-Loss Treatment

Early findings suggest promising results, but long-term safety data remain limited and are under active investigation

Retrieved from GLP-1 Agonists

GIP (glucose-dependent insulinotropic polypeptide) helps regulate blood sugar and may improve how the body handles fat

This study was designed to test whether AOD9604 could damage DNA or cause genetic mutationsimportant safety questions for any compound being considered for human use

For individuals who don't have insurance coverage and can't afford brand-name medications, compounded options through telehealth platforms may make GLP-1 treatment financially feasible

Generationally, 10% were baby boomers, 39% were Gen X, 43% were millennials, and 7% were Gen Z